Rockwell Medical price target lowered to $4 from $5 at Maxim

Maxim lowered the firm’s price target on Rockwell Medical (RMTI) to $4 from $5 and keeps a Buy rating on the shares. The firm cites the company’s Q4 results with net sales below better-than-expected preliminary net sales, the analyst tells investors in a research note. Maxim further notes that while Rockwell continues to position itself within the at-home dialysis market, a growing segment that now accounts for roughly 10% of the total hemodialysis market, the firm is reducing its estimates given continued pressure from lower DaVita (DVA) contribution and limited visibility on certain revenue contributions.